Peptide Regulators Are Splitting on Two Continents. The Sublingual Pivot Still Has No Human Data Behind It.

The number everyone will quote is 46. That is how many suspect peptide parcels Swiss authorities checked on June 22, and they kept 23 of them.

The other 23 were released, because the quantities sat inside personal import limits. It reads like a crackdown on injectables, but the record is narrower and odder than that. Swissmedic (the Swiss drug regulator) calls injections the riskiest format, yet its campaign targeted peptides and comparable substances broadly.

A month later, an FDA advisory panel voted to back compounding of BPC-157, a peptide sold for tissue repair. Two regulators, opposite directions. Somewhere between them, needle free versions are being formulated and sold.

Start in Bern. Swissmedic's own notice says the campaign, run with Swiss customs and Swiss Sport Integrity (the doping watchdog), retained 23 of 46 checked parcels. Sport Integrity classed 21 as doping agents; Swissmedic classed two as medicinal products.

About 80 percent of the checked parcels came from Poland. Recipients of the released parcels were told in a letter that they use the contents at their own risk. Swissmedic singles out injectables as particularly risky, since sterility, stability and composition cannot be guaranteed, but the campaign was not limited to them.

The release does not say which peptides were inside, and 46 parcels is a small sample, not a market measurement.

Now Washington. FDA put BPC-157 on its Category 2 list (substances flagged as safety concerns for pharmacy compounding, meaning custom preparation) in 2023, then took it off in April, which is not approval.

On July 23 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding it to the list pharmacies may compound from.

The vote is nonbinding, and FDA's own staff scientists told the panel the quality data is thin.

The only peer reviewed backing for the needle free route is a March review in Frontiers in Drug Delivery by Sarfaraz Niazi, and it is a sceptical paper.

It argues that swallowed peptides mostly fail, that liposome and nanoparticle carriers disappointed in humans, and that sublingual (under the tongue) and buccal (cheek) delivery only partly avoid first pass metabolism (the liver breaking down a dose before it reaches the blood), leaving absorption well below injection. It never mentions BPC-157.

Then the sellers. Mountain Valley MD, a small Canadian listed company, said on May 29 that it had finished initial sublingual formulation on BPC-157 and four other peptides, with dosing still being finalised.

Its release says the route avoids first pass loss entirely; the review says partly. I use the more conservative wording. Lakeland Drug Company lists a liposomal BPC-157 (wrapped in fat bubbles) at $139.95 for one fluid ounce, marked sold out on September 24.

In the United States, the likely winners of a BPC-157 listing are compounding pharmacies and telehealth platforms. ABC News notes that HHS has faced criticism that many newly appointed panel members carry financial conflicts of interest. That describes the panel's makeup, not the vote's merit, and 8 to 6 is not a landslide.

In Switzerland, the exposure sits with sellers. Swissmedic says distributing unauthorised medicines, dropshipping included, is illegal and can bring prosecution, whatever the label says.

The release does not address needle free formats either way, so anyone assuming they are safe harbour is guessing.

Mountain Valley MD is the clearest commercial actor, and its model is licensing: it says it owns none of the peptides, and it is pitching pharmacies and telehealth channels. Its release frames the opportunity around US regulators loosening, and says any formal listing still needs rulemaking with uncertain timing. It closed a C$2 million private placement in April.

The economics run through dosing. Niazi puts swallowed peptide absorption under 1 percent, which pushes dose requirements 10 to 100 times above injection, and manufacturing cost tracks dose. Sublingual is meant to soften that.

Sellers quote high absorption figures; I could not trace any to a published human study of sublingual BPC-157.

The open question is the pitch itself: that formulators are going needle free because of enforcement.

Mountain Valley's release predates the Swiss campaign and cites US liberalisation, and I found no named company, filing or clinic linking a launch to Swiss or FDA enforcement. Treat that causal story as unconfirmed.

The more honest read here is that the needle free pivot is a bet on two things nobody has settled: that regulators keep splitting on peptides, and that absorption under the tongue is good enough to matter.

Removing the needle removes a sterility problem. It does not add a study, and in Switzerland it does not add an authorization.

Until someone publishes human absorption data for sublingual BPC-157, treat the format as packaging. Both bets are live, and neither is proven.

Operators should price the regulatory divergence, which is real and dated. Prosumers should price the biology, which is still a promise.

If you run a clinic or telehealth service in Europe weighing needle free peptide protocols, the gap between US momentum and Swiss enforcement deserves a longer conversation.